申请人:Hoffmann-La Roche Inc.
公开号:US06359138B1
公开(公告)日:2002-03-19
The present invention relates to 4-hydroxy-piperidine derivatives of the general formula
wherein
X denotes —O—, —NH—, —CH2—, —CH═, —CHOH—, —CO—, —S—, —SO— or —SO2—;
R1-R4 are, independently from each other, hydrogen, hydroxy, lower-alkyl-sulfonylamino, 1- or 2-imidazolyl or acetamido;
R5-R8 are, independently from each other, hydrogen, hydroxy, lower-alkyl, halogen, lower-alkoxy, trifluoromethyl or trifluoromethyloxy;
a and b may be a double bond, provided that when “a” is a double bond, “b” cannot be a double bond;
n is 0-2;
m is 1-3;
p is 0 or 1
and to pharmaceutically acceptable addition salts thereof.
Compounds of the present invention are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers, which can be used in mediating processes underlying development of CNS including learning and memory formation and function.
本发明涉及一般式的4-羟基哌啶衍生物,其中X代表—O—、—NH—、—CH2—、—CH═、—CHOH—、—CO—、—S—、—SO—或—SO2—;R1-R4分别是氢、羟基、较低烷基磺酰胺基、1-或2-咪唑基或乙酰胺基;R5-R8分别是氢、羟基、较低烷基、卤素、较低烷氧基、三氟甲基或三氟甲氧基;a和b可以是双键,但是当“a”是双键时,“b”不能是双键;n为0-2;m为1-3;p为0或1;以及其药学上可接受的盐。本发明的化合物是NMDA(N-甲基-D-天冬氨酸)受体亚型选择性阻断剂,可用于调节包括学习和记忆形成与功能在内的中枢神经系统发育过程。